Form 4: Enovix Director Pegah Ebrahimi Granted 22,543 Restricted Stock Units
Insider Transaction Report
Enovix Corporation's Director, Pegah Ebrahimi, was granted 22,543 restricted stock units (RSUs) on June 12, 2025, as part of her compensation.
Summary
- Enovix Corporation (ENVX) Director Pegah Ebrahimi was granted 22,543 shares in the form of Restricted Stock Units (RSUs) on June 12, 2025.
- These RSUs were granted at a price of $0, indicating they are part of a compensation package.
- The RSUs will vest in four equal installments of 25% each on September 12, 2025, December 12, 2025, March 12, 2026, and the earlier of June 12, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.
- Vesting is contingent upon Ms. Ebrahimi's continuous service as a director through each applicable vesting date.
- Following this transaction, Pegah Ebrahimi beneficially owns a total of 66,640 shares of Enovix common stock, which includes 26,325 shares issuable from previously granted RSUs.
Sentiment
Score: 7
Explanation: The grant of RSUs to a director is a positive sign of continued alignment between management/board and shareholder interests, and is a routine, expected event in corporate governance.
Positives
- The grant of Restricted Stock Units to a director aligns their interests with those of the shareholders, as the value of their compensation is tied to the company's stock performance.
- This is a standard form of equity compensation for directors, indicating ongoing commitment and incentivization.
Future Outlook
The document outlines the future vesting schedule for the granted Restricted Stock Units, with installments occurring on September 12, 2025, December 12, 2025, March 12, 2026, and the earlier of June 12, 2026, or the 2026 annual meeting date, subject to continuous service.
Industry Context
This Form 4 filing details a routine equity compensation grant to a director, which is a common practice across publicly traded companies to incentivize and retain key personnel by aligning their financial interests with long-term shareholder value. It does not provide broader industry trends or competitive insights.
Related Party Transactions
- The grant of 22,543 Restricted Stock Units to Pegah Ebrahimi, a Director of Enovix Corporation, constitutes a related party transaction as it involves compensation to a member of the company's board.
Stakeholder Impact
- Shareholders: The RSU grant aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders through improved long-term value creation.
- Employees: While not directly impacting general employees, such grants are part of a broader compensation philosophy that can influence overall company culture and retention strategies for key personnel.
Next Steps
- Vesting of 25% of RSUs on September 12, 2025.
- Vesting of 25% of RSUs on December 12, 2025.
- Vesting of 25% of RSUs on March 12, 2026.
- Vesting of the final 25% of RSUs on the earlier of June 12, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.
Key Dates
| Date | Description |
|---|---|
| 06/12/2025 | Date of RSU grant to Pegah Ebrahimi. |
| 06/13/2025 | Date the Form 4 filing was signed. |
| 09/12/2025 | First vesting date for 25% of the granted RSUs. |
| 12/12/2025 | Second vesting date for 25% of the granted RSUs. |
| 03/12/2026 | Third vesting date for 25% of the granted RSUs. |
| 06/12/2026 | Fourth vesting date for the remaining 25% of the granted RSUs, or the date of the Issuer's 2026 annual meeting of stockholders, whichever is earlier. |
Keywords
Enovix, ENVX, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.